USP 〈1037〉: What the New PAT Chapter Means for Your DACH Strategy

Category: Regulatory & Standards | Process Analytical Technology (PAT) | Quality Strategy Author: Dusko Kadijevic, Publisher Analytic Journal Last updated: June 2026 Reading time: approx. 12 minutes Target audience: PAT engineers, regulatory affairs, QA managers, process engineers in the pharmaceutical industry

Definition

USP General Chapter 〈1037〉 is a newly developed chapter of the United States Pharmacopeia (USP) that describes PAT as a lifecycle topic for the first time — from method development through continuous monitoring to data-driven optimization. The chapter positions PAT as an integral component of modern pharmaceutical quality strategies and explicitly links it to Quality by Design (QbD), Continued Process Verification (CPV), and Real-Time Release Testing (RTRT).

The draft was released for public comment in May 2025 in the Pharmacopeial Forum 51(4). As of June 2026, the comment period is still ongoing. The final chapter is expected to become binding for FDA-regulated facilities in the US from approximately 2027.

Why 〈1037〉 Is Relevant for DACH Facilities Too

The most common reaction to a new USP chapter in German pharmaceutical facilities is: "We operate under EMA, not FDA — this doesn't directly concern us." This position was defensible ten years ago. Today it is a risk.

Three developments make 〈1037〉 essential reading for European facilities as well:

First: International harmonization is no longer a future project. The ICH guidelines Q8 through Q12 are jointly developed and implemented by the FDA, EMA, and other authorities. In this context, USP 〈1037〉 is not an isolated solution — it is a concrete operationalization of what is already embedded in ICH Q10 (Pharmaceutical Quality System).

Second: Those who manufacture globally or hold FDA approvals already operate under both systems. For these facilities, 〈1037〉 is not optional — it is a reference document.

Third: The chapter formulates for the first time a structured, regulatory-endorsed framework for the complete lifecycle of a PAT method. This framework is technically sound — regardless of which authority formally requires it.

What 〈1037〉 Actually Does — and What Sets It Apart

The Four Lifecycle Phases per 〈1037〉

USP 〈1037〉 divides PAT into four sequential phases:

Phase	Content	Practical Relevance
Design & Development	Method concept, target parameter definition, system architecture	Decision: which PAT method for which CQA?
Monitoring & Control	Continuous performance monitoring, risk-based control strategies	Day-to-day operations: SPC, alarm thresholds, drift monitoring
Method Verification / Revalidation	Verification after changes, revalidation on systematic drift	Required after method changes, raw material changes, instrument replacement
Continuous Improvement	Data-driven optimization based on accumulated process data	Long-term: model updates, expansion of design spaces

The key difference from earlier documents: PAT is no longer treated as a one-time project ("method developed, validated, done"), but as a continuous management process with defined transitions between phases.

Comparison: 〈1037〉 vs. Existing Reference Documents

Document	Issuer	PAT Focus	Lifecycle Approach	DACH Status
FDA PAT Guidance (2004)	FDA	Introduction of PAT concepts	Point-in-time — no lifecycle structure	Guidance only, not binding
ICH Q8 (R2)	ICH	Pharmaceutical Development, Design Space	Development phase	EMA-implemented, binding
ICH Q10	ICH	Pharmaceutical Quality System	Lifecycle approach for QS	EMA-implemented, binding
ICH Q12	ICH	Lifecycle Management, Post-Approval Changes	Change management	EMA-implemented, binding
EMA PAT Reflection Paper (2006)	EMA	Regulatory principles for PAT	Limited	Guidance only
USP 〈1037〉 (Draft 2025)	USP	PAT across the complete lifecycle	Complete — four phases	Comment period; not yet binding

Assessment: 〈1037〉 closes a real gap. Neither the FDA Guidance from 2004 nor the EMA Reflection Paper describes how a PAT method should be managed after validation. ICH Q10 and Q12 provide the framework, but no PAT-specific operationalization. That is precisely what 〈1037〉 delivers.

The Lifecycle Problem: What Goes Wrong in Practice

Scenario: Inline NIR After Three Years of Operation

A mid-sized DACH pharmaceutical facility introduces inline NIR for moisture determination in a granulation process four years ago. The method is developed, validated, and accepted by regulators. The project is considered a success.

Three years later, the system begins to read systematically outside specification. The evidence is clear: calibration drift. The cause is complex — a raw material supplier change, a minimal shift in particle size distribution, accumulated probe contamination from insufficient cleaning intervals.

The real problem: there is no documented procedure defining when a NIR method must be revalidated, what data triggers this, and who makes the decision. The quality system only kicks in when the system is already out-of-spec — not before.

This is precisely the situation for which 〈1037〉 provides a framework. The "Method Verification / Revalidation" phase defines risk-based triggers for revalidation. The "Continuous Improvement" phase provides the basis for systematically evaluating calibration data and detecting drift early — not only after the alarm triggers.

Regulatory Classification: What 〈1037〉 Is — and Is Not

Timeline

Date	Status
May 2025	Draft published in Pharmacopeial Forum 51(4) for public comment
2025–2026	Comment period — no binding force
As of June 2026	Still in comment process
Expected from 2027	Official USP chapter — binding for FDA-regulated facilities in the US

What 〈1037〉 Is Not

〈1037〉 is not an EU standard and not an EMA document. There is no direct regulatory obligation for facilities operating exclusively under EMA oversight. It is also not a technical standard in the ISO or DIN sense.

〈1037〉 is a pharmacopoeial chapter with guidance function — comparable to other USP General Chapters describing technical best practices. Its practical significance lies not in compulsion, but in its signal: what the USP formalizes in a General Chapter describes the state of the art within a regulatory-endorsed framework.

Regulatory Standards Overview

Document	Issuer	Year	Content (Summary)	Binding in DACH
ICH Q8 (R2)	ICH / EMA	2009	Pharmaceutical Development, Design Space concept	Binding (EMA-implemented)
ICH Q9 (R1)	ICH / EMA	2023	Quality Risk Management — updated version	Binding
ICH Q10	ICH / EMA	2008	Pharmaceutical Quality System, lifecycle approach	Binding
ICH Q12	ICH / EMA	2019	Lifecycle Management, Post-Approval Changes	Binding
FDA PAT Guidance	FDA	2004	Introduction of PAT concepts, risk-based approach	Guidance for FDA approvals
EMA PAT Reflection Paper	EMA	2006	Regulatory principles, expectations for PAT	Guidance only
USP 〈1037〉	USP	2025 (Draft)	PAT as lifecycle topic, four phases	Comment period; binding from ca. 2027 for FDA-regulated facilities

What PAT Managers in DACH Should Do Now

〈1037〉 is still in the comment period — this is not a reason for passivity, but a time window.

1. Submit Comments (before comment deadline) USP explicitly publishes drafts for industry comment. European facilities operating PAT systems have technical expertise that can feed into the final document.

2. Inventory: Where Does Your PAT System Stand in Its Lifecycle? For each operational PAT method in your facility, ask: Does a documented process exist for revalidation triggers, drift monitoring, and continuous improvement? If not — 〈1037〉 now provides a recognized structural template.

3. Read ICH Q10 and 〈1037〉 Together Those who have already implemented ICH Q10 are closer to 〈1037〉 than they might think. The next step is the PAT-specific operationalization of the lifecycle structures already in place.

4. Review Global Approvals Those holding or planning FDA approvals: 〈1037〉 will be a reference in the FDA-regulated environment from approximately 2027. Preparation starts now.

FAQ — Frequently Asked Questions

What is USP General Chapter 〈1037〉? USP 〈1037〉 is a chapter of the United States Pharmacopeia that describes PAT as a complete lifecycle process for the first time. It divides PAT into four phases: method development, monitoring and process control, verification and revalidation, and continuous improvement. The draft was published for public comment in May 2025.

Is USP 〈1037〉 binding for pharmaceutical facilities in Germany or the EU? No — as of June 2026, 〈1037〉 is neither binding nor formally incorporated into the European regulatory framework. Facilities operating exclusively under EMA oversight are not directly obligated. However, those holding or planning FDA approvals must treat 〈1037〉 as a reference once it takes effect.

What is the difference between 〈1037〉 and the FDA PAT Guidance from 2004? The FDA Guidance from 2004 introduced PAT as a concept and established the risk-based approach — but it primarily describes the introduction phase. USP 〈1037〉 closes the gap that follows: it defines how a PAT method should be managed after validation, across its complete operational lifetime.

What is Real-Time Release Testing (RTRT) and how does it relate to 〈1037〉? Real-Time Release Testing is the release of a batch segment based on real-time process data instead of conventional end-of-batch laboratory testing. PAT methods are the technical foundation for RTRT. USP 〈1037〉 creates with its lifecycle approach the framework necessary to make RTRT regulatorily defensible.

What is the most common error when implementing PAT systems? The most common error is treating PAT as a completed project. Method developed, validated, regulatorily accepted — and then operated as a static system until the first out-of-spec event. Without documented revalidation triggers, a drift monitoring concept, and a defined improvement process, risk accumulates silently in the background.

Conclusion

USP 〈1037〉 is the first pharmacopoeial document that consistently describes PAT as a management task across the complete lifecycle — not as measurement technology, but as quality strategy. For DACH facilities, it is not a mandatory document, but a reliable reference framework that closes a real gap between ICH principles and PAT practice. Those who operate PAT systems long-term while serving or planning FDA markets should not treat 〈1037〉 as a US niche topic — but as a preview of the future harmonized standard.

Sources

Document	Issuer	Year	Content
USP General Chapter 〈1037〉 (Draft)	United States Pharmacopeia	2025	PAT as lifecycle process in four phases
ICH Q8 (R2): Pharmaceutical Development	ICH	2009	Design Space, QbD fundamentals
ICH Q9 (R1): Quality Risk Management	ICH	2023	Updated quality risk management
ICH Q10: Pharmaceutical Quality System	ICH	2008	Lifecycle framework for pharmaceutical QS
ICH Q12: Lifecycle Management	ICH	2019	Post-Approval Changes, Lifecycle Management
PAT Guidance: A Framework for Innovative Pharmaceutical Development	FDA	2004	Foundational document for PAT in pharmaceuticals
Reflection Paper on PAT	EMA	2006	Regulatory principles for PAT in the EU

Analytic Journal — The Portal for PAT Dusko Kadijevic | Publisher Analytic Journal Written June 2026. Based on the USP 〈1037〉 draft (Pharmacopeial Forum 51(4), May 2025). Updates following completion of the comment period will be incorporated.